Siobhan is a co-founder and the CEO/Managing Director of KVS. A veterinarian with robust experience diagnosing and treating a wide range of cancers in private practice in NZ and the UK, Siobhan is passionate about the potential of Kode Technology to make affordable therapeutic and diagnostic care solutions more accessible to vet clinics worldwide, starting with the Kv9 injectable cancer treatment. As a start-up CEO Siobhan is leading the company into its first clinical trials of Kv9 starting in March 2025.

Steve is a co-founder and the CTO at KVS. Steve also holds several other external roles including  Professor Emeritus at AUT University, CEO/Managing director of Kode Biotech Ltd (a Kode Technology licensing company), GlycoNZ Ltd (a research product supply company) and Kode Agalimmune Ltd (an immuno oncology therapeutic start-up). Steve a Fellow of the Royal Society of New Zealand, invented the Kode Technology platform which now has resulted a range of research tools and diagnostic reagents, and which has over a hundred academic journal papers written about it. Kode Technology is a unique cell/virus/liposome surface modification platform technology with multiple uses in therapeutics and diagnostics. (https://hdl.handle.net/2292/62953 ) The KVS active ingredient Kv9, is a Kode technology construct.

John is a Kode Biotech appointee to the Kode Veterinary Science board. John is also a shareholder and director of Kode Biotech Ltd and Kode Agalimmune Ltd. An experienced entrepreneur, company director and CEO, John has been a past head judge for the New Zealand Marketing Awards and is the current head judge for the Research Effectiveness Awards. John has founded seven startups and mentored over 130 companies in growth strategies and digital transformation.

Selwyn has an extensive background in drug development, medical devices, natural products and related technology, product development and manufacturing. He was the Business Development Manager at NZ Pharmaceuticals - a GMP certified manufacturer of drug substances and pharmaceutical intermediates. He co-managed a drug development program while at NZP, partnering with the USA National Human Genome Research Institute, a division of the US National Institutes of Health, to develop a drug to treat a rare disease. Selwyn is now a biotech business consultant and professional Director with two Chair and three Board positions on start-up and tech organisations. He is on the Board of the Te Awa Community Foundation, a charity to enhance our communities for future generations.